Equillium, Inc. (NASDAQ:EQ) insider Stephen Connelly sold 13,539 shares of the business’s stock in a transaction on Friday, June 4th. The shares were sold at an average price of $7.01, for a total transaction of $94,908.39. Following the sale, the insider now directly owns 999,509 shares of the company’s stock, valued at $7,006,558.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Stephen Connelly also recently made the following trade(s):
- On Tuesday, June 8th, Stephen Connelly sold 10,495 shares of Equillium stock. The stock was sold at an average price of $7.18, for a total transaction of $75,354.10.
EQ stock opened at $6.98 on Friday. The stock has a market capitalization of $202.70 million, a price-to-earnings ratio of -5.09 and a beta of 1.62. The firm’s 50-day moving average price is $6.41. Equillium, Inc. has a one year low of $2.53 and a one year high of $27.05. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.08.
Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in shares of Equillium during the fourth quarter valued at about $82,000. Hsbc Holdings PLC acquired a new position in shares of Equillium during the fourth quarter valued at about $94,000. Virtu Financial LLC acquired a new position in shares of Equillium during the fourth quarter valued at about $98,000. Squarepoint Ops LLC acquired a new position in shares of Equillium during the fourth quarter valued at about $108,000. Finally, Jane Street Group LLC acquired a new position in shares of Equillium during the fourth quarter valued at about $114,000. 26.34% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently weighed in on EQ shares. Jonestrading started coverage on shares of Equillium in a research note on Wednesday, March 3rd. They issued a “buy” rating and a $14.00 price objective for the company. SVB Leerink reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Equillium in a research note on Tuesday, May 18th. Finally, Zacks Investment Research lowered shares of Equillium from a “buy” rating to a “hold” rating in a research note on Thursday, February 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Equillium presently has a consensus rating of “Buy” and an average price target of $13.29.
Equillium Company Profile
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Further Reading: Dividend Yield
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.